The Mary M. Gooley Hemophilia Center is licensed by the New York State Board of Pharmacy. The Center can provide your enrollees with coordinated clinical care (by licensed, board-certified hematologists) and clotting agents (including value-priced factor replacement products) to treat any bleeding disorder effectively and efficiently.
People affected by hemophilia exhibit the potential for extraordinarily high health care costs, due in large part to their reliance on clotting factor products. The Center is a closely managed, regional non-profit provider organization which integrates specialty pharmacy and multi-disciplinary clinical care to produce effective, efficient results for people affected by hemophilia and other bleeding disorders.
The Center is a member of the Hemophilia Alliance, a national organization, currently comprised of 95 Hemophilia Treatment Centers nationwide. The purpose of the Alliance is to assist its members in providing outstanding care for their patients. See information at the following link: http://hemoalliance.org/third-party-payers/
A study on Medicaid patients in Missouri served through an integrated Hemophilia Treatment Center pharmacy illustrates the potential for savings as a result of HTC management of these specialized needs: read a summary here.
Integrating pharmacy services with the provision of clinical care contributes to seamless, timely, informed care – the kind of health care experience your enrollees want and need. Being cared for at the Center and using factor appropriately result in fewer bleeding-related health complications, translating to fewer visits to emergency departments, fewer hospital admissions and better health.
It’s a simple fact that our prices are lower AND our medical team (available to our patients 24 hours/day x 365 days a year) gives close attention to each case, promoting patients’ personal responsibility and ensuring judicious use of factor (contact us to compare the aggregate cost of insurance claims for our hemophilia patients to claims for hemophilia care your company pays in any other community).
As the Rochester region’s only federally recognized comprehensive hemophilia treatment center (HTC), we operate a Public Health Service/340B Pharmacy for eligible patients. Discounts provided to the Center via the 340B program allow the Center to dispense clotting factor at prices lower than other pharmacies’ prices, saving money for insurance payers – maybe millions of dollars, depending on how much factor is used.
The Center is part of a network of about 130 HTCs nationwide, funded by the Health Resources Services Administration (HRSA), a network of excellence for care of people affected by hemophilia and other bleeding disorders. A comprehensive Hemophilia Treatment Center provides a broad scope of services that has been well described by the National Hemophilia Foundation, the Centers for Disease Control and Prevention and the federal Office of Maternal and Child Health (a HRSA agency).
Center patients with bleeding disorders experience fewer bleeding-related complications, fewer visits to area emergency departments, fewer hospitalizations and high patient satisfaction.
For eligible patients, the Center purchases clotting factor products at a significant discount (PHS / 340B pharmacy discount program). Furthermore, the Center is an enrolled participating member of the Hemophilia Alliance (www.hemoalliance.org), via which we gain access to competitive prices, including sub 340B ceiling-prices in some cases. Those savings translate into lower prices for insurance payers.
Furthermore, the existence of a national treatment center network makes Hemophilia Treatment Centers the logical choice for clotting factor and for the care of people affected by hemophilia and other bleeding disorders.
